122 related articles for article (PubMed ID: 35113285)
1. First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.
Berlin J; Tolcher AW; Ding C; Whisenant JG; Horak ID; Wood DL; Nadler PI; Hansen UH; Lantto J; Skartved NJØ; Pedersen MW; Patnaik A
Invest New Drugs; 2022 Jun; 40(3):586-595. PubMed ID: 35113285
[TBL] [Abstract][Full Text] [Related]
2. Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.
Juric D; Dienstmann R; Cervantes A; Hidalgo M; Messersmith W; Blumenschein GR; Tabernero J; Roda D; Calles A; Jimeno A; Wang X; Bohórquez SS; Leddy C; Littman C; Kapp AV; Shames DS; Penuel E; Amler LC; Pirzkall A; Baselga J
Clin Cancer Res; 2015 Jun; 21(11):2462-70. PubMed ID: 26034219
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
Moore KN; Borghaei H; O'Malley DM; Jeong W; Seward SM; Bauer TM; Perez RP; Matulonis UA; Running KL; Zhang X; Ponte JF; Ruiz-Soto R; Birrer MJ
Cancer; 2017 Aug; 123(16):3080-3087. PubMed ID: 28440955
[TBL] [Abstract][Full Text] [Related]
4. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
[TBL] [Abstract][Full Text] [Related]
5. A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.
Reynolds KL; Bedard PL; Lee SH; Lin CC; Tabernero J; Alsina M; Cohen E; Baselga J; Blumenschein G; Graham DM; Garrido-Laguna I; Juric D; Sharma S; Salgia R; Seroutou A; Tian X; Fernandez R; Morozov A; Sheng Q; Ramkumar T; Zubel A; Bang YJ
BMC Cancer; 2017 Sep; 17(1):646. PubMed ID: 28899363
[TBL] [Abstract][Full Text] [Related]
6. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
7. A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors.
Doi T; Shitara K; Kojima T; Yoshino T; Dontabhaktuni A; Rebscher H; Tang S; Cosaert J; Ohtsu A
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1253-62. PubMed ID: 27139036
[TBL] [Abstract][Full Text] [Related]
8. A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors.
Oh DY; Lee KW; Han SW; Kim JW; Shin JW; Jo SJ; Won J; Hahn S; Lee H; Kim WH; Bang YJ
Oncologist; 2019 Aug; 24(8):1037-e636. PubMed ID: 31164456
[TBL] [Abstract][Full Text] [Related]
9. Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study.
LoRusso PM; Krishnamurthi S; Youssoufian H; Hall N; Fox F; Dontabhaktuni A; Grebennik D; Remick S
Invest New Drugs; 2014 Apr; 32(2):303-11. PubMed ID: 23903897
[TBL] [Abstract][Full Text] [Related]
10. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
Strickler JH; Weekes CD; Nemunaitis J; Ramanathan RK; Heist RS; Morgensztern D; Angevin E; Bauer TM; Yue H; Motwani M; Parikh A; Reilly EB; Afar D; Naumovski L; Kelly K
J Clin Oncol; 2018 Nov; 36(33):3298-3306. PubMed ID: 30285518
[TBL] [Abstract][Full Text] [Related]
11. A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.
Falchook GS; Peeters M; Rottey S; Dirix LY; Obermannova R; Cohen JE; Perets R; Frommer RS; Bauer TM; Wang JS; Carvajal RD; Sabari J; Chapman S; Zhang W; Calderon B; Peterson DA
Invest New Drugs; 2021 Oct; 39(5):1284-1297. PubMed ID: 33852104
[TBL] [Abstract][Full Text] [Related]
12. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors.
Paz-Ares LG; Gomez-Roca C; Delord JP; Cervantes A; Markman B; Corral J; Soria JC; Bergé Y; Roda D; Russell-Yarde F; Hollingsworth S; Baselga J; Umana P; Manenti L; Tabernero J
J Clin Oncol; 2011 Oct; 29(28):3783-90. PubMed ID: 21900113
[TBL] [Abstract][Full Text] [Related]
13. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.
Gordon MS; Sweeney CS; Mendelson DS; Eckhardt SG; Anderson A; Beaupre DM; Branstetter D; Burgess TL; Coxon A; Deng H; Kaplan-Lefko P; Leitch IM; Oliner KS; Yan L; Zhu M; Gore L
Clin Cancer Res; 2010 Jan; 16(2):699-710. PubMed ID: 20068101
[TBL] [Abstract][Full Text] [Related]
14. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies.
Weiner LM; Belldegrun AS; Crawford J; Tolcher AW; Lockbaum P; Arends RH; Navale L; Amado RG; Schwab G; Figlin RA
Clin Cancer Res; 2008 Jan; 14(2):502-8. PubMed ID: 18223225
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.
Vlahovic G; Meadows KL; Uronis HE; Morse MA; Blobe GC; Riedel RF; Zafar SY; Alvarez-Secord A; Gockerman J; Starodub AN; Ready NE; Anderson EL; Bendell JC; Hurwitz HI
Cancer Chemother Pharmacol; 2012 Jul; 70(1):95-102. PubMed ID: 22638798
[TBL] [Abstract][Full Text] [Related]
16. A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors.
Smith DC; Chugh R; Patnaik A; Papadopoulos KP; Wang M; Kapoun AM; Xu L; Dupont J; Stagg RJ; Tolcher A
Invest New Drugs; 2019 Aug; 37(4):722-730. PubMed ID: 30591982
[TBL] [Abstract][Full Text] [Related]
17. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study.
Gazzah A; Bedard PL; Hierro C; Kang YK; Abdul Razak A; Ryu MH; Demers B; Fagniez N; Henry C; Hospitel M; Soria JC; Tabernero J
Ann Oncol; 2022 Apr; 33(4):416-425. PubMed ID: 35026412
[TBL] [Abstract][Full Text] [Related]
18. Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies.
Almhanna K; Kalebic T; Cruz C; Faris JE; Ryan DP; Jung J; Wyant T; Fasanmade AA; Messersmith W; Rodon J
Clin Cancer Res; 2016 Oct; 22(20):5049-5057. PubMed ID: 27178743
[TBL] [Abstract][Full Text] [Related]
19. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.
Jänne PA; Boss DS; Camidge DR; Britten CD; Engelman JA; Garon EB; Guo F; Wong S; Liang J; Letrent S; Millham R; Taylor I; Eckhardt SG; Schellens JH
Clin Cancer Res; 2011 Mar; 17(5):1131-9. PubMed ID: 21220471
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors.
LoRusso PM; Gounder M; Jalal SI; André V; Kambhampati SRP; Loizos N; Hall J; Holzer TR; Nasir A; Cosaert J; Kauh J; Chiorean EG
Invest New Drugs; 2017 Aug; 35(4):442-450. PubMed ID: 28161886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
